OKYO Pharma [OKYO] - Last Close: $1.94
A clinical update is boosting shares of OKYO Pharma
This morning, the tiny pharma firm said it completed enrollment for a Phase 2 clinical trial of OK-101 to treat dry eye disease.
OKYO has enrolled a total of 240 patients for the study since it first began in May of this year.
The company expects the last patient visit to occur in the last week of November, and top-line data could be available as soon as December.
OKYO is up 22.6% in response to the clinical update.
My Take: OKYO could be worth watching as we approach the end of the year. The stock could get another big boost in December if the final trial data supports an approval of OK-101.
Plus Therapeutics [PSTV] - Last Close: $2.97
Plus Therapeutics just landed a promising deal.
This morning, the biotech firm said it entered into an exclusive license agreement for Biocept's CNSide CF-based tumor cell capture & enumeration platform.
Plus Therapeutics noted that it had positive experiences using CNSide during drug trials, and it believes the technology has "significant diagnostic potential."
Biocept will receive $150,000 worth of PSTV common stock in exchange for the license, and the deal also includes a $1 million licensing option.
PSTV is up 15.8% on elevated trading volume in response to the news.
My Take: PSTV has struggled to pass the $3 mark, but this rally could give it the final push it needs to break into a new trading range.
Zyversa Therapeutics [ZVSA] - Last Close: $0.1229
Zyversa is taking off after an upbeat analyst note.
Analysts at HC Wainwright initiated coverage on the micro-float this morning with a "buy" rating and a $2.50 price target.
The bullish price target is more than 20-times the stock's Thursday closing price.
ZVSA took off as soon as the note hit the market. Shares are currently up 44.0% on active trading volume.
My Take: This has been a very volatile rally, so I wouldn't be surprised if most of ZVSA's gains evaporated before the end of today's trading session.
AGBA Group [AGBA] - Last Close: $0.709
AGBA Group is treding after landing a major institutional investment.
After Thursday's close, the Hong Kong-based financial services firm announced a $50 million equity purchase agreement with Williamsburg Ventures Holdings.
Under the agreement, Williamsburg will invest $50 million into ordinary shares of AGBA over the next 36 months.
AGBA says the equity facility will "enhance [its] capitalization and financing flexibility" and enhance shareholder value.
AGBA is one of today's top premarket performers with a 36.8% gain on active trading volume.
My Take: AGBA's chart is pretty ugly, and China stocks are almost always unpredictable. Approach with caution.
